Overview

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

Status:
Not yet recruiting

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."

Phase:

Phase 2

Details

Lead Sponsor:

Maimónides Biomedical Research Institute of Córdoba

Collaborator:

MERCK SHARP & DOHME DE ESPAÑA S.A.

Treatments:

Letermovir